1-15 of 813
Understanding Variability in Myasthenia Gravis
NeuroFrontiersUnderstanding Variability in Myasthenia Gravis
Henry Kaminski, MD
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiersExamining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP
Austin Larson, MD
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
NeuroFrontiersMicroglia Drive Neurodegeneration in Friedreich’s Ataxia
Ryan Quigley
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiersUnpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiersFriedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
- advertisement
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiersIs Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiersSPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
BCMA mRNA CAR-T Shows Durable Benefit in MG
NeuroFrontiersBCMA mRNA CAR-T Shows Durable Benefit in MG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiersRAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
NeuroFrontiersNext-Generation MS Care: The Promise of Cell-Based Therapeutics
Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
NeuroFrontiersOmaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
- advertisement
FA hiPSCs in Translational Drug Development
NeuroFrontiersFA hiPSCs in Translational Drug Development
Proactive Pregnancy Planning and Reproductive Care in MS
NeuroFrontiersProactive Pregnancy Planning and Reproductive Care in MS
Riley Bove, MD, MMSc
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
NeuroFrontiersApplying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Aaron Miller, MD
